Gujarat Kidney Super Speciality Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Gujarat Kidney & Super Speciality Ltd is ₹ 163.5 as of 30 Oct 15:30 . The P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 51.4 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Yatharth Hospital & Trauma Care Services Ltd changed from 31.3 on March 2024 to 33.9 on March 2026 . This represents a CAGR of 2.70% over 3 years The Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 798.29 crore on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 3582 crore on March 2024 to ₹ 5946 crore on March 2026 . This represents a CAGR of 18.40% over 3 years The revenue of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 34.98 crore as compare to the Mar '26 revenue of ₹ 31.29 crore. This represent the growth of 11.79% The revenue of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 397.01 crore as compare to the Mar '26 revenue of ₹ 348.67 crore. This represent the growth of 13.86% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 9.07 crore as compare to the Mar '26 ebitda of ₹ 7.01 crore. This represent the growth of 29.39% The ebitda of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 96.04 crore as compare to the Mar '26 ebitda of ₹ 87.02 crore. This represent the growth of 10.37% The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 5.32 crore over 9 quarters. This represents a CAGR of 29.77% The net profit of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 30.38 crore to ₹ 45.42 crore over 9 quarters. This represents a CAGR of 19.57% The Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Yatharth Hospital & Trauma Care Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Gujarat Kidney & Super Speciality Ltd

Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad. The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.

About Yatharth Hospital & Trauma Care Services Ltd

Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008.
On November 3, 2021, the status converted into a Public Company and name of the Company was changed to Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC. Yatharth Hospitals and Trauma Care Services Limited is a network of super speciality hospitals across Delhi National Capital Region (NCR) and Madhya Pradesh, capitalising on the robust healthcare infrastructure in these regions to serve a wide patient base in need of tertiary care. The Company operate three super specialty hospitals in Delhi NCR, i.e., at Greater Noida, Uttar Pradesh.
The super speciality tertiary care hospital currently operates with 400 beds, including 112 critical care beds and 9 modular operation theatres, among other surgical facilities.

FAQs for the comparison of Gujarat Kidney & Super Speciality Ltd and Yatharth Hospital & Trauma Care Services Ltd

Which company has a larger market capitalization, Gujarat Kidney & Super Speciality Ltd or Yatharth Hospital & Trauma Care Services Ltd?

Market cap of Gujarat Kidney & Super Speciality Ltd is 1,289 Cr while Market cap of Yatharth Hospital & Trauma Care Services Ltd is 8,942 Cr

What are the key factors driving the stock performance of Gujarat Kidney & Super Speciality Ltd and Yatharth Hospital & Trauma Care Services Ltd?

The stock performance of Gujarat Kidney & Super Speciality Ltd and Yatharth Hospital & Trauma Care Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Kidney & Super Speciality Ltd and Yatharth Hospital & Trauma Care Services Ltd?

As of October 31, 2026, the Gujarat Kidney & Super Speciality Ltd stock price is INR ₹163.5. On the other hand, Yatharth Hospital & Trauma Care Services Ltd stock price is INR ₹928.05.

How do dividend payouts of Gujarat Kidney & Super Speciality Ltd and Yatharth Hospital & Trauma Care Services Ltd compare?

To compare the dividend payouts of Gujarat Kidney & Super Speciality Ltd and Yatharth Hospital & Trauma Care Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.